Estrella Immunopharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.29next fiscal year
Monitoring Framework
Key Performance Indicators
EB103 STARLIGHT-1 Phase I Complete Response (CR) Rate in High-Dose Cohort Quarterly100.0%
EB103 STARLIGHT-1 Phase I Treatment-Related Serious Adverse Events (SAEs) Quarterly0.0
Cash and Cash Equivalents (USD) Quarterly1.4MTarget: Maintain sufficient runway for clinical trials
Watch Items
- Going Concern Risk and Capital RunwayTrigger: Cash reserves falling below 6 months of operational burnAction: Execute additional equity financing, PIPE transactions, or strategic partnerships to extend runway.
- Nasdaq Listing ComplianceTrigger: Failure to maintain minimum bid price of $1.00 or market value requirementsAction: Implement share consolidation (reverse stock split) or execute capital market strategies to regain compliance.
- EB103 Phase II Trial Enrollment and DosingTrigger: Slower-than-expected patient recruitment or safety signals in Phase IIAction: Activate additional clinical trial sites and engage with the Data Safety Monitoring Board (DSMB).
Research as of 19 Jun 2026